Products
Loading...

ERBB2

More+
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. ERBB2, commonly referred to as HER2, is amplified and/or overexpressed in 20-30% of invasive breast carcinomas. HER2-positive breast cancer is treated in a separate manner from other subtypes of breast cancer. Metastatic HER2-positive breast cancer is now commonly treated with HER2-targeted therapy. Apart from being amplified/overexpressed, ERBB2 activating mutations have been shown to have clinical importance in HER2-negative breast cancer. These mutations have shown sensitivity to the tyrosine kinase inhibitor neratinib, and highlight the importance of clinical sequencing efforts in treating breast cancer.

Species Reactivity:
Human
Application:
Cytotoxicity assay, Function study
Species Reactivity:
Human
Application:
Cytotoxicity assay, Function study
Species Reactivity:
Human
Application:
Cytotoxicity assay, Function study
Species Reactivity:
Human
Application:
Cytotoxicity assay, Function study
Species Reactivity:
Human
Application:
Cytotoxicity assay, Function study
Species Reactivity:
Human
Application:
Cytotoxicity assay, Function study
Species Reactivity:
Human
Application:
Cytotoxicity assay, Function study
Species Reactivity:
Human
Application:
Cytotoxicity assay, Function study
Species Reactivity:
Human
Application:
Cytotoxicity assay, Function study
Species Reactivity:
Human
Application:
Cytotoxicity assay, Function study
Target:
Her-2 receptor
Linker:
2, 4 or 6 Phor18 molecules
Target:
HER2
Drug:
Gly5-modified DM1 (Gly5-modified N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
Target:
HER2
Linker:
VC-PAB (valine-citrulline-p-aminobenzoyloxycarbonyl)
Drug:
MMAE (Monomethyl auristatin E)
Target:
HER2
Linker:
MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl)
Drug:
MMAF (Monomethyl auristatin F)
Target:
HER2
Linker:
Mc (maleimidocaproyl)
Drug:
MMAF (Monomethyl auristatin F)
Target:
HER2
Linker:
BMPEO (bis-maleimido-trioxyethylene glycol)
Drug:
DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
Target:
HER2
Linker:
BMPEO (bis-maleimido-trioxyethylene glycol)
Drug:
DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
Target:
Her2
Linker:
ALKYNE
Drug:
MMAF (Monomethyl auristatin F)
Target:
Her2
Linker:
valine-citruline-p-amino-benzoyl-carbonate (VCP)-cyclooctyne
Drug:
MMAF (Monomethyl auristatin F)
Target:
HER2
Linker:
MT-VC
Drug:
(S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
Target:
HER2
Linker:
MT-VC
Drug:
(S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide